1 / 9

predict

www.predict.net. Prediction BioSciences. Founded in 2009 ‘theranostics’- drug/diagnostic combinations Oncology and Neuro/Cardiovascular indications Using molecular markers to determine progression or safety/efficacy Novel approach Advanced mathematical (informatic) methods

ronald
Télécharger la présentation

predict

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. www.predict.net BioTuesday 2010

  2. Prediction BioSciences • Founded in 2009 • ‘theranostics’- drug/diagnostic combinations • Oncology and Neuro/Cardiovascular indications • Using molecular markers to determine progression or safety/efficacy • Novel approach • Advanced mathematical (informatic) methods • Statistical pattern recognition • Intelligently combine multiple markers/features into accurate predictive algorithms BioTuesday 2010

  3. Stroke TheranosticRapidResponse c-FnTMEnhanced thrombolytic BioTuesday 2010

  4. Hemorrhagic Transformation • Occurs in 30-50% of all thrombolytic-treated patients BioTuesday 2010

  5. RapidResponse c-FnTM Cellular Fibronectin (c-Fn) • Adhesive dimeric glycoprotein • Fibronectin family • Usually confined to vascular endothelium No Vascular DamageLow plasma c-Fn level Vascular Damage Increased plasma c-Fn level BioTuesday 2010

  6. c-Fn Single Marker Test Plasma c-Fn Levels BAD CANDIDATES FOR ‘LYTIC mg/ml GOOD CANDIDATES FOR ‘LYTIC BioTuesday 2010

  7. Insight™ Dx BREAST CANCER PROFILE BioTuesday 2010

  8. Insight™ Dx Breast Cancer Profile: parameters and algorithm • Molecular markers (8 selected from >60 studied) • IHC • ER • PGR • ERBB2/HER2 • BCL2 • CDKN1B/p27/Kip1 • EGFR • TP53 • ISH • MYC • Clinicopathologic data • tumor grade • tumor size • lymph node status (pN) • Algorithm • Personalized risk of recurrence score (0 to 10+) • Risk category (e.g., low vs. high) • Likelihood of future event (e.g., distant metastasis, disease-related death, and/or overall survival) BioTuesday 2010

  9. Sample Test Report BioTuesday 2010

More Related